Pharmaceutical Corruption News Articles

Excerpts of key news articles on

Below are key excerpts of revealing news articles on pharmaceutical industry corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

For further exploration, delve into our comprehensive Health and Food Corruption Information Center.

Note: Explore our full index to revealing excerpts of key major media news articles on dozens of engaging topics. And read excerpts from 20 of the most revealing news articles ever published.

Moderna set off a frenzy on Wall Street earlier this month when it announced positive, preliminary results from its coronavirus vaccine trial. As the hype grew, the young biotech company and its leading investor wasted no time capitalizing on the briefly surging stock price. Even as critics accused Moderna of overhyping the results released on May 18, a series of transactions were executed before its share price fizzled over the next week. The timing of those deals, former SEC officials said, appear to be "highly problematic" and should be investigated for potential illegal market manipulation. Just hours after revealing the promising vaccine results, Moderna (MRNA) sold 17.6 million shares to the public. That share sale, unveiled after the closing bell on May 18, was priced at $76; Moderna traded at just $48 as recently as May 6. The deal instantly raised $1.3 billion. Two of Moderna's top executives also cashed in on the boom at their company, which had suddenly amassed a $29 billion market value despite the fact it has no marketed products. By the time the selling was disclosed to the public via securities filings, Moderna's stock price had crashed back to Earth. The timing of the transactions - coupled with concerns from some medical experts that Moderna overstated the significance of its Phase 1 vaccine trial - should be investigated by authorities. Thomas Gorman, [a] former SEC official, said the agency should "absolutely" be investigating the situation at Moderna.

Note: Why didn't the media report that the Moderna vaccine trial had a 20% serious injury rate in the high dose group? Learn about this and much more in this revealing article. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

In May 2008, as the opioid epidemic was raging in America, a representative of the nation’s largest manufacturer of opioid pain pills sent an email to a client at a wholesale drug distributor in Ohio. Victor Borelli, a national account manager for Mallinckrodt, told Steve Cochrane, the vice president of sales for KeySource Medical, to check his inventories and “[i]f you are low, order more. If you are okay, order a little more, Capesce?” Then Borelli joked, “destroy this email ... Is that really possible? Oh Well...” Those email excerpts are quoted in a 144-page plaintiffs’ filing along with thousands of pages of documents unsealed by a judge’s order Friday in a landmark case in Cleveland against many of the largest companies in the drug industry. A Drug Enforcement Administration database released earlier in the week revealed that the companies had inundated the nation with 76 billion oxycodone and hydrocodone pills from 2006 through 2012. Nearly 2,000 cities, counties and towns are alleging that the companies knowingly flooded their communities with opioids, fueling an epidemic that has killed more than 200,000. The filing by plaintiffs depict some drug company employees as driven by profits and undeterred by the knowledge that their products were wreaking havoc across the country. Plaintiffs in the case argue that the actions of some of America’s biggest and best-known companies - including Mallinckrodt, Cardinal Health, McKesson, Walgreens, CVS, Walmart and Purdue Pharma - amounted to a civil racketeering enterprise.

Note: For more along these lines, see concise summaries of deeply revealing news articles on pharmaceutical industry corruption from reliable major media sources.

The Trump administration is discussing policies that would make it harder and more expensive for pharmaceutical companies to advertise directly to patients, in a move that could disrupt more than $10 billion in annual ad spending. Although the US is the only place, besides New Zealand, where pharma companies can directly advertise, banning pharma ads outright could make the administration vulnerable to lawsuits, so it's instead focusing on cutting down on the practice by adding legal and financial hurdles. The two policies the administration has focused in on would be to require greater disclosures of side effects of a drug within each ad – likely making broadcast ads much longer and prohibitively expensive – or removing the industry's ability to deduct direct-to-consumer advertising as a business expense for tax purposes. The new policies could threaten a key source of revenue to advertising and media companies, as well as the US pharmaceutical industry. Companies spent $10.8 billion in 2024 on direct-to-consumer pharmaceutical advertising in total. Before the loosening of advertising regulations by the Food and Drug Administration in 1997, US pharma companies had to list all possible side effects for a medication if they wanted to mention which condition the drug being advertised was intended to treat. Reading out a list of side effects took so long it drove up the cost for air time and meant there wasn't as much broadcast advertising as there is today.

Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption.

Outro Health [is] a telehealth startup that CEO and cofounder Brandon Goode describes as "Uber for getting off antidepressants." Outro officially launched in the US last month and is currently available in seven states. The startup is betting that many of the growing number of Americans taking antidepressants will eventually want help coming off them. Over 11 percent of US adults took medication for depression in 2023. Research has found the prevalence of adverse withdrawal symptoms may be much higher, particularly among patients who have been on them for long periods. Outro pairs patients with a clinician who meets with them on a custom schedule and guides them through a tailored tapering program. Outro currently employs a small group of medical contractors, including nurse practitioners specializing in psychiatry and general nurse practitioners, who are supervised by psychiatrists. [British academic psychiatrist and co-founder of Outro] Mark Horowitz ... was driven by his own harrowing experience coming off antidepressants ... when he was a psychiatry doctoral student. Severe insomnia and dizziness were so debilitating ...It took me years to come off, not weeks as guidelines recommended." After he recovered, Horowitz began pushing for doctors to adopt new clinical guidelines for getting off antidepressants. He coauthored the Royal College of Psychiatry's guidance for psychiatric drug cessation and joined the UK's National Health Service as a clinical research fellow. "To me, it is actually a very leftist issue to de-medicalize the way we treat anxiety and depression," [Horowitz] says, noting that such illnesses are often caused "by social circumstances, by poverty, by loneliness."

Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption and mental health.

Patients prescribed drugs for movement disorders - including restless leg syndrome (RLS) - say doctors did not warn them about serious side effects that led them to seek out risky sexual behaviour. Twenty women have told the BBC that the drugs - given to them for RLS, which causes an irresistible urge to move - ruined their lives. A report by drugs firm GSK - seen by the BBC - shows it learned in 2003 of a link between the medicines, known as dopamine agonist drugs, and what it described as "deviant" sexual behaviour. It cited a case of a man who had sexually assaulted a child while taking the drug for Parkinson's. Some of the women who described being drawn to risky sexual behaviour told us they had no idea of what was causing it. Others said they felt compelled to gamble or shop with no history of such activities. Impulsive behaviours, including gambling and increased sex drive, have long been listed as side effects in medicine leaflets for dopamine agonist drugs - and are thought to affect between 6% to 17% of RLS patients taking them, according to health guidance body NICE. The cases of what the GSK report from 2003 described as "deviant behaviour" involved two men who were prescribed Ropinirole for Parkinson's disease. In one, a 63-year-old-man sexually assaulted a seven-year-old girl, leading to a custodial sentence. In the second case, a 45-year-old man carried out "uncontrolled acts of exhibitionism and indecent behaviour".

Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption.

Antidepressants are frequently prescribed to people with dementia for symptoms like anxiety, depression, aggressiveness and sleeplessness. But a specific class of antidepressant medications - selective serotonin reuptake inhibitors (SSRIs) - actually might speed up brain decline among some dementia patients, a new Swedish study suggests. Heavier doses of certain SSRIs are tied to a higher risk for severe dementia, researchers reported in a new study ... in the journal BMC Medicine. The SSRI drug escitalopram was associated with the fastest cognitive decline, followed by citalopram and sertraline. For the study, researchers tracked the brain health of more than 18,700 patients enlisted in the Swedish Registry for Cognitive/Dementia Disorders between May 2007 and Oct. 2018. The patients' average age was 78. During an average follow-up of more than four years, about 23% of patients received a new prescription for an antidepressant, researchers said. SSRIs were the most commonly prescribed antidepressant, amounting to 65% of all those prescriptions, the study says. "Higher dispensed doses of SSRIs were associated with higher risk for severe dementia, fractures, and all-cause mortality," the researchers concluded. "These findings highlight the significance of careful and regular monitoring to assess the risks and benefits of different antidepressants use in patients with dementia."

Note: For more along these lines, read our concise summaries of news articles on Big Pharma corruption.

The former head of the Food and Drug Administration's (FDA) drug division is joining Pfizer as its chief medical officer. Patrizia Cavazzoni was formerly director of the FDA's Center for Drug Evaluation and Research (CDER) from 2020 until January, when she resigned just ahead of President Trump's return to office. Cavazzoni previously worked at Pfizer prior to joining the FDA in 2018. The announcement spurred renewed criticisms about the common "revolving door" between the FDA and industry. Critics worry the close relationship leads to a quid pro quo and favoritism toward industry. Scott Gottlieb, FDA commissioner during Trump's first term, now serves on the board of Pfizer. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has long accused the FDA of being corrupt and beholden to industry influence and has pledged to root out supposed conflicts of interest across the agency. Just ahead of the election, while Trump was considering him for HHS secretary, Kennedy posted on social media that FDA employees who are "part of this corrupt system" should "pack their bags." Watchdog group Public Citizen panned Cavazzoni's hiring. "Cavazonni's move demonstrates that the revolving door between the FDA and the industries it regulates is alive and well and continues to undermine the FDA's credibility as a public health agency," the organization's health research group director Robert Steinbrook said.

Note: For more along these lines, read our concise summaries of news articles on corruption in government and in Big Pharma.

New rules require drugmakers to be clearer and more direct when explaining their medications' risks and side effects. The [new] guidelines ... are designed to do away with industry practices that downplay or distract viewers from risk information. But while regulators were drafting them, a new trend emerged: Thousands of pharma influencers pushing drugs online with little oversight. A new bill in Congress would compel the FDA to more aggressively police such promotions on social media platforms. "Some people become very attached to social media influencers and ascribe to them credibility that, in some cases, they don't deserve," said Tony Cox ... at Indiana University. Still, TV remains the industry's primary advertising format, with over $4 billion spent in the past year. Even so, many companies are looking beyond TV and expanding into social media. They often partner with patient influencers who post about managing their conditions, new treatments or navigating the health system. Advertising executives say companies like the format because it's cheaper than TV and consumers generally feel influencers are more trustworthy than companies. "The power of social media and the deluge of misleading promotions has meant too many young people are receiving medical advice from influencers instead of their health care professional," Sens. Dick Durbin of Illinois and Mike Braun of Indiana wrote the FDA in a February letter.

Note: Prescription drug advertising is only legal in the US and New Zealand. Read more about the influencers who are paid to promote pharmaceuticals on social media. For more along these lines, read our concise summaries of news articles on Big Pharma profiteering and media manipulation.

A New Zealand man was recently arrested after allegedly illegally accessing COVID-19 vaccine data from the country's health agency. Barry Young, 56, a former IT employee at Te Whatu Ora, the country's health agency, was arrested and accused of illegally obtaining COVID-19 vaccine data and sharing it on the internet. Young appeared on Infowars, where he was interviewed by ... Alex Jones. "I just looked at the data and what I was seeing, since the rollout, it just blew my mind. I was just seeing more and more people dying that shouldn't have been dying. It was just obvious," Young told Jones. The incident comes as COVID-19 vaccine skeptics have continued to question the efficacy of the inoculation. Texas Attorney General Ken Paxton recently announced that he was suing vaccine manufacturer Pfizer "for unlawfully misrepresenting the effectiveness of the company's COVID-19 vaccine and attempting to censor public discussion of the product." During the interview with Infowars, Young explained that he had suspicions about the COVID-19 vaccine in New Zealand since its rollout. "I want people to analyze this, I want people to look at it...we need to open it up and the government needs to have an inquiry about it. Just bring it to the public's attention," Young said.

Note: U.S.-based genomics scientist Kevin McKernan had uploaded Barry Young's data onto a file hosting service, MEGA, only to have his whole account deleted by MEGA overnight. For more along these lines, see concise summaries of deeply revealing news articles on COVID vaccine problems from reliable major media sources.

Pfizer's plan to as much as quadruple U.S. prices for its COVID-19 vaccine next year is beyond Wall Street's expectations and will spur its revenue for years despite weaker than anticipated demand for the new booster shot so far, analysts said. The drugmaker, which developed and sells the vaccine with Germany's BioNTech, said on Thursday evening that it is targeting a range of $110 to $130 a dose for the vaccine once the United States moves to a commercial market next year. Analysts said the move could lead to price hikes by rivals. The companies have varied the pricing during the pandemic, with wealthy countries paying the most for the shots and the poorest countries the least. Wells Fargo analyst Mohit Bansal said the new pricing range for the vaccine could add around $2.5 billion to $3 billion in annual revenue for Pfizer. "This is much higher than our assumption of $50 per shot," Bansal wrote in a research note. Global vaccine access group the People's Vaccine Alliance, which has pushed for Pfizer to allow cheaper copies of the vaccine to be made, called the proposed price hike "daylight robbery." The price range announced by Pfizer represented a more than 10,000% markup over what experts have estimated it costs the vaccine makers to produce the shots.

Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.

Public health initiatives in the United States are suffering from a crisis of trust. Recent polls show that only a third of the public trusts insurance and pharmaceutical companies, while just 56 percent trust the government health agencies that are meant to regulate these industries. Another survey during the COVID-19 pandemic showed that only around half of Americans have a "great deal" of trust in the CDC, while a mere third have such trust in the Department of Health and Human Services. When the mRNA vaccines for COVID-19 were made available to the public free of charge, a national conversation began about "vaccine hesitancy"–the phenomenon of Americans choosing not to be vaccinated even when incentivized and, in some cases, coerced. Americans had watched public health experts lie, misdirect, ignore evidence and yield to professional pressure. Few wanted to be their guinea pigs. Not all the COVID-19 gaslighting was the fault of the media or politicians - much was implemented by experts abusing their apolitical position of trust. The experts ... including Drs. Deborah Birx and Anthony Fauci, insisted on the most asinine and evidence-free preventative measures, including facial coverings, lockdowns and social distancing. Their insulated role as health advisers enabled them to manipulate health policy in ways that benefited only themselves. The most stark example was the corruption of data collection at the Center for Disease Control–a scandal that crashed public trust to a new low.

Note: For more along these lines, see concise summaries of deeply revealing news articles on government corruption and the coronavirus from reliable major media sources.

A foundation representing the vaccine maker BioNTech has been accused of seeking to undermine the World Health Organization's initiative to bring covid vaccine manufacturing to the African continent. The kENUP Foundation, a consultancy hired by BioNTech, has claimed that WHO's hub, which is creating a covid-19 mRNA vaccine that African companies can make, is unlikely to be successful and will infringe on patents, documents obtained by The BMJ have shown. Instead, they show kENUP promoting BioNTech's proposal to ship mRNA factories housed in sea containers from Europe to Africa, initially staffed with BioNTech workers, and a proposed new regulatory pathway to approve the vaccines made in these factories. The novel pathway has been described as paternalistic and unworkable. The move threatens the pan-African venture backed by WHO that seeks to scale up African production of lifesaving vaccines from 1% to 60% by 2040. WHO's technology transfer hub, launched in June 2021 and based in South Africa, uses publicly available information to recreate Moderna's vaccine, to teach companies and scientists across the continent how to use mRNA technology. It will then develop a comparable vaccine, which, if successful in clinical trials and approved by regulators, it will manufacture industrially. In a document sent to South African government officials after a visit to the country on 11-14 August last year, the kENUP Foundation said that the hub's activity should be stopped.

Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines and Big Pharma profiteering from reliable major media sources

Pfizer Inc wants to intervene in a Texas federal lawsuit seeking information from the U.S. Food and Drug Administration used in licensing the company's COVID-19 vaccine, a litigation move that plaintiffs who are suing for the data say is premature. Pfizer's lawyers at DLA Piper told U.S. District Judge Mark Pittman on Jan. 21 it wanted a role in the proceedings to help the FDA avoid "inappropriately" disclosing trade secret and confidential commercial information. On Tuesday night, the group of doctors and scientists who sued last year over public access to the FDA's Pfizer licensing records said in a court filing that the company's bid to jump into the lawsuit was untimely because the plaintiffs have not challenged any redactions to requested records. Earlier this month, the judge ordered a fast-track release of hundreds of thousands of documents, calling the case "of paramount public importance." U.S. government agencies control the release of information under federal public-records laws, but companies can challenge and even sue to block the disclosure of certain details. The FDA earlier drew criticism over its plan to release 500 pages a month in response to the lawsuit from Public Health and Medical Professionals for Transparency, a production schedule that would take more than 50 years to complete. In its filing, Pfizer said the company supports public disclosure of FDA records "to promote transparency and the public's confidence in the vaccine."

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption and coronavirus vaccines from reliable major media sources.

A new generation of Covid-19 treatments will soon be available, and they matter more than many people realize. They have the potential to substantially reduce hospitalization and death. In the simplest terms, they can help turn Covid into a more ordinary respiratory disease, similar to the common cold or flu, rather than one that's killing about 1,000 Americans a day and dominating daily life for millions. Two treatments are on the way – one from Pfizer and one from Merck – and they will have both medical and psychological benefits. Not only can they reduce serious Covid illness, but they can also reduce Covid fears and help society move back to normalcy. Both Pfizer's and Merck's treatments are pill regimens that people take for five days after a positive Covid test. The pills prevent the virus from replicating inside the body and are broadly similar to treatments that revolutionized H.I.V. care in the 1990s. In truth, the virus has already been largely defanged. The death rate for vaccinated adults under 50 is virtually zero. Pfizer has projected that it will produce enough doses to treat 20 million people in the first half of next year. The Biden administration has agreed to buy 10 million of the treatments, known as Paxlovid, at a cost of about $530 each. Merck projects that it will produce more than 10 million courses of its drug, called molnupiravir, by the end of this year. The federal government has agreed to buy 3.1 million of those courses for around $700 each.

Note: And thus big Pharma is set to receive another huge windfall. Why are they setting prices so how and raking in huge profits when so many are suffering financially? For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus from reliable major media sources.

Pfizer reported that earnings and sales more than doubled in the past quarter, and it raised its outlook for results the full year, thanks greatly to its Covid-19 vaccine. The company reported adjusted earnings of $7.7 billion, up 133% from a year earlier. Revenue soared to $24.1 billion, up 134%. Both easily cleared results forecast by analysts. The vaccine business alone was responsible for more than 60% of the company's sales, as vaccine revenue rose to $14.6 billion from only $1.7 billion a year earlier. The company said its Covid vaccine sales accounted for $13 billion of that revenue. Revenue outside of its Covid vaccine business was up a far more modest 7%. This year, the Covid vaccine has brought in revenue of $24.3 billion. And Pfizer said it expects a total of $36 billion from the vaccine for all of 2021 – nearly $12 billion more in revenue the final quarter of the year. And it said based on contracts it now has signed it expects revenue $29 billion from the Covid vaccine in 2022. The company said it now expects full-year 2021 revenue of between $81 billion to $82 billion, up $2 billion from its earlier guidance. It also raised its earnings per share outlook by about 3% to 5% above what it had been expected to earn. About 67% of the total US population has had a least one dose of a Covid vaccine, and 58% are fully vaccinated, according to data tracked by the Mayo Clinic.

Note: Explore hundreds of personal stories of severe vaccine injury and death that are being strongly suppressed by government and the major media. An MD's excellent research reveals that the government knew about and actively suppressed safe, effective, low-price treatments for COVID and targeted physicians who prescribed them. For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines and Big Pharma profiteering from reliable major media sources.

As Purdue Pharma seeks approval for a controversial bankruptcy settlement, it has retained the services of highly compensated lobbying firms Brownstein Hyatt Farber Schreck and Capitol Hill Consulting Group. At the Purdue Pharma bankruptcy trial that began Thursday, Judge Robert Drain is widely expected to approve a proposed settlement of the Purdue Pharma bankruptcy that would release members of the billionaire Sackler family, the company's owners, from all current and future opioid-related civil claims. In the year and a half leading up to the trial, Purdue spent at least $1.2 million on federal lobbying expenses as it worked toward the settlement, an Intercept review of lobbying records shows. If the settlement is approved, the Sacklers will be making a contribution of $4.28 billion, which will leave them with over $6 billion at minimum in total assets – money that will be effectively untouchable by opioid crisis victims, even though it is Purdue going bankrupt, not the Sacklers. "This whole bankruptcy was the Sacklers trying to buy immunity," said activist Ed Bisch, who lost his son to an OxyContin overdose in 2001 and is a claimant and active opponent of the settlement. "The only question was what would be the price." Among the lobbyists paid by Purdue Pharma – maker of the opioid painkiller OxyContin – since it filed for bankruptcy reorganization in September 2019 are politically connected Brownstein Hyatt, which received $480,000, and Capitol Hill Consulting Group, which got $300,000.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

Johnson & Johnson is exploring a plan to offload liabilities from widespread Baby Powder litigation into a newly created business that would then seek bankruptcy protection. During settlement discussions, one of the health-care conglomerate's attorneys has told plaintiffs' lawyers that J&J could pursue the bankruptcy plan, which could result in lower payouts for cases that do not settle beforehand. Plaintiffs' lawyers would initially be unable to stop J&J from taking such a step. J&J faces legal actions from tens of thousands of plaintiffs alleging its Baby Powder and other talc products contained asbestos and caused cancer. The plaintiffs include women suffering from ovarian cancer and others battling mesothelioma. Should J&J proceed, plaintiffs who have not settled could find themselves in protracted bankruptcy proceedings with a likely much smaller company. Future payouts to plaintiffs would be dependent on how J&J decides to fund the entity housing its talc liabilities. J&J is now considering using Texas's "divisive merger" law, which allows a company to split into at least two entities. For J&J, that could create a new entity housing talc liabilities that would then file for bankruptcy to halt litigation. The maneuver is known among legal experts as a Texas two-step bankruptcy. A 2018 Reuters investigation found J&J knew for decades that asbestos, a known carcinogen, lurked in its Baby Powder and other cosmetic talc products.

Note: Can we trust this company with vaccines? For more along these lines, see concise summaries of deeply revealing news articles on corporate corruption from reliable major media sources.

The factory that Pfizer Inc. plans to use to boost production of its covid-19 vaccine for the massive U.S. inoculation effort was cited by federal inspectors last year for repeated quality-control violations. Food and Drug Administration inspectors visited the McPherson, Kansas, plant at the end of 2019 into January 2020, according to an inspection report. They found the drug giant released medications for sale after failing to thoroughly review quality issues that arose in routine testing, the report shows. Additionally, the report says inspectors found bacteria and mold in supposedly sterile areas, an issue seen in previous visits to the facility. And the plant failed to properly sample drug products to ensure they didn't have excessive levels of certain toxins, the inspectors wrote. The FDA sent Pfizer a warning letter, the agency's strongest rebuke, concerning the factory in 2017 after the agency detected issues similar to those it found in 2020. The FDA concluded that Pfizer had addressed the violations in June 2018, a month before it returned to the facility and found more problems. The company plans to supply the U.S. with 200 million doses of its two-shot vaccine regimen by the end of May. The FDA halted all inspections of drugmaking facilities at the beginning of the Covid-19 pandemic, though it has since resumed some domestic visits. Pfizer's plant in Kansas is also authorized to make the Covid-19 treatment remdesivir.

Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines and Big Pharma corruption from reliable major media sources.

Carlos is a Mexican businessman. Two associates accompanied him as he travelled [to] India. There, [he] met Manu Gupta, a businessman active in a variety of sectors. On 25 September 2018 he was arrested in the city of Indore, Madhya Pradesh, along with a Mexican associate and an Indian chemist. The three men were wearing masks and gloves – and were in possession of more than 10kg of fentanyl – an ultra-potent synthetic opioid. The case sheds light on the international networks which Mexican cartels have built up – and the business methods they employ to dominate the lucrative fentanyl market. Fentanyl increasingly displaced heroin on the underground market, causing record numbers of overdoses around the world. In 2018, fentanyl and similar synthetic drugs accounted for nearly half of the 67,367 drug overdose deaths in the US. This year, overdoses have rocketed during the coronavirus pandemic, with more than 40 US states reporting an increase in drug mortality rates – particularly from synthetic opioids like fentanyl. In theory, sales of precursors are highly regulated. In reality, the extent of the problem is revealed with a simple Google search. Entering keywords for fentanyl precursors quickly leads you to the social network Pinterest, where – nestled between wedding moodboards and home decor inspiration – are posts from Chinese companies offering fentanyl precursors for export – many directed towards Mexico.

Note: Pharmaceutical executives have been caught bribing doctors to prescribe fentanyl-containing painkillers. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

The development of the antibody cocktail used to treat President Donald Trump for Covid-19 – which he heralded as a cure for the disease – was funded largely by the U.S. government, yet the Trump administration has apparently failed to set any guarantees that the treatment would be affordable. The biopharmaceutical company Regeneron, led by the two highest paid executives in the industry, received hundreds of millions in public funds during the research and development of the antibody therapy, and now stands to make a killing from its potentially lifesaving treatment. In January ... Regeneron struck an agreement with a division of Department of Health and Human Services known as the Biomedical Advanced Research and Development Authority, or BARDA, to receive up to $81 million for work on antibodies that would prevent Covid-19 from infecting cells by attaching to the spikes on its surface. The two antibodies Regeneron chose were developed using cell lines that were derived from the kidney tissue of an aborted fetus. The January contract [lacks] a standard clause that ensures interventions developed with government funding are available to the public "on reasonable terms." While Trump promised that the government would provide the antibody cocktail to Americans for free, drug pricing efforts say that many people probably won't have access to the treatment at all, let alone at an affordable price. "You have massive public investment, but ... it doesn't benefit public health," [said drug pricing expert Zain Rizvi].

Note: For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma profiteering from reliable major media sources.

Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.